Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells.
Animals
Cell Line
Cell Line, Tumor
Cell Movement
/ ethics
Cell Proliferation
/ genetics
Female
HEK293 Cells
Humans
MAP Kinase Kinase Kinases
/ genetics
MCF-7 Cells
Mice
NF-kappa B
/ genetics
Neoplasm Invasiveness
/ genetics
Signal Transduction
/ genetics
Transcriptome
/ genetics
Triple Negative Breast Neoplasms
/ genetics
Up-Regulation
/ genetics
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
12
06
2018
accepted:
23
11
2018
revised:
23
10
2018
pubmed:
16
12
2018
medline:
30
4
2019
entrez:
16
12
2018
Statut:
ppublish
Résumé
Metastasis to distant organs is a major cause for solid cancer mortality, and the acquisition of migratory and invasive phenotype is a key factor in initiation of malignancy. In this study we investigated the contribution of Mixed-Lineage Kinase 4 (MLK4) to aggressive phenotype of breast cancer cells. Our TCGA cancer genomic data analysis revealed that amplification or mRNA upregulation of MLK4 occurred in 23% of invasive breast carcinoma cases. To find the association between MLK4 expression and the specific subtype of breast cancer, we performed a transcriptomic analysis of multiple datasets, which showed that MLK4 is highly expressed in triple-negative breast cancer compared to other molecular subtypes. Depletion of MLK4 in cell lines with high MLK4 expression impaired proliferation and anchorage-dependent colony formation. Moreover, silencing of MLK4 expression significantly reduced the migratory potential and invasiveness of breast cancer cells as well as the number of spheroids formed in 3D cultures. These in vitro findings translate into slower rate of tumor growth in mice upon MLK4 knock-down. Furthermore, we established that MLK4 activates NF-κB signaling and promotes a mesenchymal phenotype in breast cancer cells. Immunohistochemical staining of samples obtained from breast cancer patients revealed a strong positive correlation between high expression of MLK4 and metastatic potential of tumors, which was predominantly observed in TNBC subgroup. Taken together, our results show that high expression of MLK4 promotes migratory and invasive phenotype of breast cancer and may represent a novel target for anticancer treatment.
Identifiants
pubmed: 30552384
doi: 10.1038/s41388-018-0618-0
pii: 10.1038/s41388-018-0618-0
pmc: PMC6484767
doi:
Substances chimiques
NF-kappa B
0
MAP Kinase Kinase Kinases
EC 2.7.11.25
MAP3K21 protein, human
EC 2.7.11.25
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2860-2875Références
Nat Rev Mol Cell Biol. 2002 Sep;3(9):663-72
pubmed: 12209126
Science. 2003 May 9;300(5621):949
pubmed: 12738854
J Clin Invest. 2004 Aug;114(4):569-81
pubmed: 15314694
J Clin Oncol. 2006 Dec 20;24(36):5652-7
pubmed: 17116942
Nat Methods. 2007 Apr;4(4):359-65
pubmed: 17396127
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Cancer Res. 2008 Mar 1;68(5):1462-70
pubmed: 18316610
Cancer Cell. 2009 May 5;15(5):416-28
pubmed: 19411070
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Eur J Cancer. 2010 May;46(7):1177-80
pubmed: 20307970
Breast Cancer Res Treat. 2011 Apr;126(2):407-20
pubmed: 20490655
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell Mol Immunol. 2012 Jan;9(1):27-33
pubmed: 21602844
Ann Oncol. 2011 Aug;22(8):1736-47
pubmed: 21709140
Oncogene. 2012 Mar 1;31(9):1196-206
pubmed: 21785460
Cancer Res. 2012 Mar 1;72(5):1290-300
pubmed: 22253230
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Drug Discov Today. 2013 Mar;18(5-6):240-9
pubmed: 23073387
Cancer Res. 2013 Mar 15;73(6):1912-21
pubmed: 23319808
Oncogenesis. 2012 Mar 26;1:e6
pubmed: 23552557
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
J Vis Exp. 2014 Apr 25;(86):null
pubmed: 24797513
Nat Commun. 2014 May 22;5:3901
pubmed: 24849047
World J Clin Oncol. 2014 Aug 10;5(3):412-24
pubmed: 25114856
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
PLoS One. 2015 Apr 07;10(4):e0122333
pubmed: 25848952
Breast. 2015 Nov;24 Suppl 2:S26-35
pubmed: 26253814
Arch Gynecol Obstet. 2016 Feb;293(2):247-69
pubmed: 26341644
Cell. 2015 Oct 8;163(2):506-19
pubmed: 26451490
Trends Pharmacol Sci. 2015 Dec;36(12):822-846
pubmed: 26538316
Cancer Res. 2016 Feb 1;76(3):724-35
pubmed: 26637668
Cancer Cell. 2016 Feb 8;29(2):201-13
pubmed: 26859459
J Cell Physiol. 2017 Jun;232(6):1337-1345
pubmed: 27662245
PLoS One. 2017 Jan 20;12(1):e0169622
pubmed: 28107418
Trends Cancer. 2017 Jun;3(6):391-406
pubmed: 28670628
Cell Signal. 2017 Nov;39:66-73
pubmed: 28757353
J Biol Chem. 1997 Aug 22;272(34):21096-103
pubmed: 9261113